title: [Optimization of the treatment of anxiety disorders with selank].
abstract: OBJECTIVE
  To compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders.
  
  
  METHODS
  Authors explored the anxiolytic effect and tolerability of monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders (ICD-10 items F40.2-9, F41.1-9, F45.0-2). Therapeutic effect was assessed clinically and with HDRS, CGI and Spilberger scales. Tolerability was evaluated using the UKU scale. Stroop test and verbal fluency test were used. Quality of life was assessed with the SF-36.
  
  
  RESULTS
  The positive effect of phenazepam was achieved earlier in the optimization of treatment with selank on HDRS. The combined treatment decreased the level of undesirable side-effects of phenazepam (attention and memory impairment, asthenia, sedation, increase in sleep duration, sexual disturbances, emotional indifference and orthostatism) during the course of treatment and after the tranquilizer withdrawal. Taken together, the therapeutic efficacy and reduction of side-effects had a positive impact on the quality-of-life of the patients treated with selank as add-on to phenazepam.
  
  
  CONCLUSIONS
  The results extend therapeutic possibilities of treatment of anxietyspectrum disorders with the combination of benzodiazepine tranquilizers and selank.
authors.affiliation: Russian Peoples Friendship University, Moscow.
authors.forename: V E
authors.initials: VE
authors.lastname: Medvedev
authors.affiliation: Menthal Health Research Center, Russian Academy of Sciences, Moscow.
authors.forename: O N
authors.initials: ON
authors.lastname: Tereshchenko
authors.affiliation: Menthal Health Research Center, Russian Academy of Sciences, Moscow.
authors.forename: N V
authors.initials: NV
authors.lastname: Kost
authors.affiliation: Russian Peoples Friendship University, Moscow; City Psychiatric Hospital #13, #71, Moscow.
authors.forename: A Yu
authors.initials: AY
authors.lastname: Ter-Israelyan
authors.affiliation: Russian Peoples Friendship University, Moscow; City Psychiatric Hospital #13, #71, Moscow.
authors.forename: E V
authors.initials: EV
authors.lastname: Gushanskaya
authors.affiliation: Russian Peoples Friendship University, Moscow.
authors.forename: I K
authors.initials: IK
authors.lastname: Chobanu
authors.affiliation: Menthal Health Research Center, Russian Academy of Sciences, Moscow.
authors.forename: O Yu
authors.initials: OY
authors.lastname: Sokolov
authors.affiliation: Menthal Health Research Center, Russian Academy of Sciences, Moscow; Institute of Molecular Genetics, Russian Academy of Sciences, Moscow.
authors.forename: N F
authors.initials: NF
authors.lastname: Myasoedov
mesh_terms: D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D055815:Young Adult
chemical_list: D014151:Anti-Anxiety Agents; D009842:Oligopeptides; D001569:Benzodiazepines; C017928:phenazepam; C100827:TP 7